Oral treatment for multiple sclerosis

The Lancet Neurology

Volumn 10, Issue 11, 2011, Pages 1026-1034

  Killestein, Joep ^a   Rudick, Richard A ^b   Polman, Chris H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; LAQUINIMOD; PLACEBO; TERIFLUNOMIDE;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSING REMITTING MULTIPLE SCLEROSIS; SHORT SURVEY;

ADMINISTRATION, ORAL; CLADRIBINE; CLINICAL TRIALS AS TOPIC; CROTONIC ACIDS; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; QUINOLONES; SPHINGOSINE; TOLUIDINES;

EID: 80054734945     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70228-9     Document Type: Short Survey

References (64)

1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995, 45:1277-1285.
2. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
5. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
7. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
8. Tremlett HL, Oger J Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003, 61:551-554.
9. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
10. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74:1463-1470.
11. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011, 76:1697-1704.
12. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
13. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362:416-426.
14. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
15. Merck Serono: Regulatory Update on Cladribine Tablets Merck Serono, (accessed Sept 15, 2011). http://www.merckserono.net/corp.merckserono_2011/en/images/20110622_en_tcm1494_76074.pdf?Version=.
16. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006, 66:894-900.
17. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092. for the LAQ/5062 Study Group.
18. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472. for the BG-12 Phase IIb Study Investigators.
19. Miller A, O'Connor P, Wolinsky JS, et al. Clinical and MRI outcomes from a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses. Neurology 2011, 76:S41.002.
20. Comi G Oral laquinimod reduced relapse rate and delayed progression of disability in allegro, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis. Neurology 2011, 76(9, suppl 4):7PP.001.
21. Results of Phase III Bravo trial TEVAPHARMA, (accessed Sept 15, 2011). http://www.tevapharm.com/en-US/Media/News/Pages/Bravo.aspx.
22. Biogen Idec announces positive top-line results from the first phase 3 trial investigating oral BG-12 (DIMETHYL FUMARATE) in multiple sclerosis Biogen Idec, (accessed Sept 15, 2011). http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1548648.
23. Aktas O, Kury P, Kieseier B, Hartung HP Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010, 6:373-382.
24. Cohen JA, Chun J Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011, 69:759-777.
25. Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol 2011, published online May 26. 10.1016/j.clim.2011.05.005.
26. Hohlfeld R, Barkhof F, Polman C Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 2011, 76:S28-S37.
27. Conway D, Cohen JA Emerging oral therapies in multiple sclerosis. Curr Neurol Neurosci Rep 2010, 10:381-388.
28. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75:403-410.
29. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
30. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011, 108:751-756.
31. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140.
32. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011, 10:520-529. on behalf of the TRANSFORMS Study Group.
33. Gold R Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011, 25:37-52.
34. Hartung HP, Aktas O, Kieseier B, Comi GC Development of oral cladribine for the treatment of multiple sclerosis. J Neurol 2010, 257:163-170.
35. Liliemark J The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997, 32:120-131.
36. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993, 81:597-601.
37. Rice GP, Filippi M, Comi G Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000, 54:1145-1155.
38. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994, 344:9-13.
39. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996, 93:1716-1720.
40. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999, 111:35-44.
41. Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011, 10:329-337. on behalf of the CLARITY study group.
42. Fontoura P, Garren H Multiple sclerosis therapies: molecular mechanisms and future. Results Probl Cell Differ 2010, 51:259-285.
43. Claussen MC, Korn T Immune mechanisms of new therapeutic strategies in MS-teriflunomide. Clin Immunol 2011, published online Feb 28. 10.1016/j.clim.2011.02.011.
44. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
45. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000, 54:1734-1741.
46. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002, 130:163-172.
47. Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42:731-739.
48. Bruck W, Wegner C Insight into the mechanism of laquinimod action. J Neurol Sci 2011, 306:173-179.
49. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64:987-991.
50. Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler 2010, 16:1360-1366.
51. Bruck W, Pfortner R, Wegner C Effect of laquinimod on Cuprizone-induced demyelination in mice. Neurology 2011, 76(9, suppl 4):P05.030.
52. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
53. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006, 13:604-610.
54. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011, 10:338-348.
55. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009, 8:254-260.
56. Uitdehaag BM, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin 2011, 27:1529-1537.
57. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon β1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898-904. the Early Treatment of Multiple Sclerosis Study Group.
58. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
59. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397. for the BENEFIT Study Group.
60. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511. for the PreCISe study group.
61. Multiple -Sclerosis (relapsing-remitting): fingolimod appraisal consultation document NICE, (accessed Sept 15, 2011). http://guidance.nice.org.uk/TA/Wave20/71.
62. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010, 9:740-750.
63. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:203-295.
64. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011, 76:1858-1865.